View Clinical Trial (Medical Research Study)

Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence - NCT00672256-27705(Clinical Trial 218836)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Durham
State:  
NC
Zip Code: 27705
Conditions: Smoking - ADHD
Purpose: The broad objective of this proposal is to identify functional neuroanatomical correlates of impairments in decision making and response inhibition during smoking abstinence. We will measure changes in performance and regional blood oxygenation levels using fMRI while smokers and non-smokers complete tasks designed to assess decision making and response inhibition. Our primary hypothesis is that smoking abstinence will result in impaired decision making and response inhibition accompanied by decreases in blood-oxygenation-level-dependent (BOLD) fMRI signal in brain regions associated with these cognitive processes including frontal cortex and the ventral striatum. Abstinence may also result in performance-related increases in activation in brain regions associated with effortful processing including the anterior cingulate cortex in effort to compensate for deficits in other regions. We also hypothesize that smokers with a history of diagnosis of ADHD will exhibit greater decreases in brain activity following smoking abstinence. Finally, we hypothesize that smokers during in the satiated state will exhibit brain activity more similar to that of non-smokers.
Study summary:
Criteria: Inclusion Criteria: - Smoker subjects must have smoked an average of 10 cigarettes per day for two continuous years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine, have an expired air carbon monoxide reading of at least 10 ppm. Non-smoker subjects must have smoked less than 50 cigarettes in their lifetime, have not smoked in the last six months, and have an expired air carbon monoxide reading of less than or equal to 5 ppm. Subjects must be in general good health. Participants with controlled medical conditions (e.g., hypertension) will be considered if treatment is not thought to interfere with fMRI measures or potentially ameliorate smoking withdrawal symptoms. Exclusion Criteria: - Individuals with a major medical condition that would make participation unsafe (e.g., have pacemaker or other metallic implant), uncomfortable (e.g., chronic pain), confound results (e.g., psychiatric condition other than ADHD (non-medicated)) suffering from claustrophobia; abnormally afraid of closed-in places will be excluded from participation. Current alcohol or drug abuse, smokeless tobacco use, or use of nicotine replacement therapy or other smoking cessation treatment will also be a basis for exclusion.
Study is available at: Duke University Medical Center
Durham, NC 27705
United States

Primary Contact:
Avery M Lutz, BA
Email: lutz0011@mc.duke.edu
Phone: 919-684-9593
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.